Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Executes the first project for developing and manufacturing a novel anticancer mAb
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
AMI to become part of Enpro’s Sealing Technologies Segment
Subscribe To Our Newsletter & Stay Updated
